All Stories

  1. Pathogenesis and current advancement in treatment and prevention strategies for Human metapneumovirus
  2. Adaptive Remodeling of the MPXV B21R Receptor-Binding Domain Enhances DC-SIGN Interaction and Identifies Conserved CTL Targets for T-Cell Vaccine Development
  3. Meeting report: The 3rd international conference of the World Society for Virology (WSV 2025) - The Virosphere of Our Cellular World
  4. Marburg virus outbreak: a global health threat, zoonotic risks, and the urgent need for international action
  5. Neuroprotective effects of Centella asiatica against LPS/amyloid beta-induced neurodegeneration through inhibition of neuroinflammation
  6. New Insights in Antibiotic Resistance and Pneumococcal Vaccines
  7. Pneumococcal Vaccination for Children
  8. Decoding the role of large heat shock proteins in the progression of neuroinflammation‐mediated neurodegenerative disorders
  9. Antibody-Dependent Enhancement During Japanese encephalitis virus Infection
  10. Clinical Characteristics and Differential Clinical Diagnosis of Japanese Encephalitis
  11. Co-infection with Other Flaviviruses During Japanese Encephalitis
  12. Global Trends in Phylogenetic Genotype-Based Epidemiology of Japanese encephalitis virus
  13. Host Immune Response During Japanese encephalitis virus Infection
  14. Impact of Japanese Encephalitis in Adults: Risk Factors and Associated Challenges
  15. Insights into the Japanese encephalitis virus-Mediated Acute Encephalitis Syndrome
  16. Japanese Encephalitis
  17. Laboratory Diagnosis of Japanese Encephalitis
  18. Molecular Diagnostics for Viral Diseases
  19. Molecular and Cellular Mechanisms Underlying Neuropathogenesis of Japanese Encephalitis
  20. Structure, Genome Organization, and Replication of Japanese encephalitis virus
  21. Survivors of Japanese Encephalitis and Associated Neuropsychiatric Complications
  22. Transmission Dynamics of Japanese encephalitis virus
  23. Transplacental Transmission of Japanese encephalitis virus
  24. Treatment Options and Antiviral Drug Discovery for Japanese Encephalitis
  25. Vaccines for Japanese Encephalitis
  26. Artificial Intelligence and Blockchain in Precision Medicine and Virology
  27. Pathogenesis, Management and Socio-Economic Impact of COVID-19 Pandemic
  28. COVID-19 and Neurodegenerative Diseases: One Health Approach
  29. One Health Approach - Advancing Global Health Security with the Sustainable Development Goals
  30. Viral Infectious Diseases Annual Volume 2024
  31. Structure-based drug designing for potential antiviral activity of selected natural product against Monkeypox (Mpox) virus and its host targets
  32. Neprilysin-Mediated Amyloid Beta Clearance and Its Therapeutic Implications in Neurodegenerative Disorders
  33. Re-emerging Chandipura vesiculovirus: A cause of concern for global health
  34. Appraisal of skeletal maturity indicators with respect to non-invasive biomarkers
  35. WSV2023 - The second meeting of the world society for virology: One health - One world - One virology
  36. Unravelling the interaction between Influenza virus and the nuclear pore complex: insights into viral replication and host immune response
  37. Desloratadine via its anti-inflammatory and antioxidative properties ameliorates TNBS-induced experimental colitis in rats
  38. HIV Treatment - New Developments
  39. Editorial: Viral emerging and re-emerging diseases: basic understanding and future intervention strategies
  40. Comparative analysis of salivary microbiota in diabetic and non-diabetic individuals of North India using metagenomics
  41. Role of Artificial Intelligence, Telehealth, and Telemedicine in Medical Virology
  42. Antiviral Strategies in the Treatment of Human and Animal Viral Infections
  43. SARS-CoV-2 Infection, Inflammation, Immunonutrition, and Pathogenesis of COVID-19
  44. Neuroprotective Effect of Levetiracetam in Combination with Berberine on Scopolamine Induced-Cognitive Impairment in Mice: A Behavioral and Biochemical Approach
  45. Transforming clinical virology with AI, machine learning and deep learning: a comprehensive review and outlook
  46. Understanding HIV-associated neurocognitive and neurodegenerative disorders (neuroAIDS): enroute to achieve the 95-95-95 target and sustainable development goal for HIV/AIDS response
  47. Appraisal of skeletal maturity indicators with respect to non invasive biomarkers
  48. Introductory Chapter: Recent Trends in Emerging and Reemerging Viral Contagions – The Day after Today
  49. Viral Outbreaks - Global Impact and Newer Horizons
  50. Dengue Fever in a One Health Perspective - Latest Research and Recent Advances
  51. Tracking the COVID-19 vaccines: The global landscape
  52. Current Topics in SARS-CoV-2/COVID-19 - Two Years After
  53. Antiviral and anti‐inflammatory activity of natural compounds against Japanese encephalitis virus via inhibition of NS5 protein and regulation of key immune and inflammatory signaling pathways
  54. Future Opportunities and Tools for Emerging Challenges for HIV/AIDS Control
  55. Antiviral and anti-inflammatory activity of novel belladonna formulation against Japanese encephalitis virus via inhibition of p65 nuclear translocation and TNF-α mediated NF-kB signaling
  56. Artificial Intelligence in Medical Virology
  57. Infectious Diseases Annual Volume 2022
  58. Fabrication and Evaluation of Basil Essential Oil-Loaded Halloysite Nanotubes in Chitosan Nanocomposite Film and Its Application in Food Packaging
  59. Pre-clinical investigation of protective effect of nutraceutical D-glucosamine on TNBS-induced colitis
  60. Tracing the origin of Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2): A systematic review and narrative synthesis
  61. Re‐emerging human monkeypox: A major public‐health debacle
  62. Trends in Molecular Aspects and Therapeutic Applications of Drug Repurposing for Infectious Diseases
  63. Drug Repurposing - Molecular Aspects and Therapeutic Applications
  64. Introductory Chapter: High-Throughput Screening - A New Tool for Precision Medicine
  65. High-Throughput Screening for Drug Discovery toward Infectious Diseases: Options and Challenges
  66. High-Throughput Screening for Drug Discovery
  67. Pneumonia
  68. Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19
  69. Chikungunya Virus - A Growing Global Public Health Threat
  70. Association between Adaptive Evolution of the Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein and Geographically Distinct Virus Epidemiology During the Initial Wave of the Coronavirus Disease 2019 Pandemic
  71. Transmission dynamics and mutational prevalence of the novel Severe acute respiratory syndrome coronavirus‐2 Omicron Variant of Concern
  72. Characterization of the novel SARS‐CoV‐2 Omicron (B.1.1.529) variant of concern and its global perspective
  73. Environmental Nanomedicine
  74. Microbicidal Nanoparticles
  75. Epstein-Barr Virus - New Trends
  76. Structural and molecular perspectives of SARS-CoV-2
  77. Therapeutic approaches for SARS-CoV-2 infection
  78. Innate Immunity in Health and Disease
  79. Pathogenesis and Host Immune Response during Japanese Encephalitis Virus Infection
  80. Multi-Organ Involvement in COVID-19: Beyond Pulmonary Manifestations
  81. Wound Healing Activity of a Novel Formulation SKRIN via Induction of Cell Cycle Progression and Inhibition of PCNA–p21 Complex Interaction Leading to Cell Survival and Proliferation
  82. Artificial Intelligence in Mental Healthcare During COVID-19 Pandemic
  83. Artificial Intelligence-Enabled Prognosis Technologies for SARS-CoV-2/COVID-19
  84. Use of Mobile Phone Apps for Contact Tracing to Control the COVID-19 Pandemic: A Literature Review
  85. Role of metabolomics in identifying cardiac hypertrophy: an overview of the past 20 years of development and future perspective
  86. Applications of Artificial Intelligence in COVID-19
  87. Zika Virus Disease: Progress and Prospects
  88. An Ophthalmological update for air-travellers during COVID-19
  89. The relevance of digital mental healthcare during COVID-19: Need for innovations
  90. Chasing COVID-19 through SARS-CoV-2 spike glycoprotein
  91. COVID-19 in the elderly people and advances in vaccination approaches
  92. Plant-based vaccines and antibodies to combat COVID-19: current status and prospects
  93. Recombinant vaccines for COVID-19
  94. Dengue Fever in a One Health Perspective
  95. Antiviral activity of traditional medicinal plants from Ayurveda against SARS-CoV-2 infection
  96. Antiviral Activity of Belladonna During Japanese Encephalitis Virus Infection via Inhibition of Microglia Activation and Inflammation Leading to Neuronal Cell Survival
  97. Mental illnesses among COVID-19 patients: Possible immunological underpinnings
  98. Viral Hepatitis E and Chronicity: A Growing Public Health Concern
  99. COVID-19: benefits and risks of passive immunotherapeutics
  100. Calcarea carbonica treatment rescues lipopolysaccharide-induced inflammatory response in human mononuclear cells via downregulation of inducible cyclooxygenase pathway
  101. Dark Classics in Chemical Neuroscience: An Evidence-Based Systematic Review of Belladonna
  102. Clinical Management and Therapeutic Strategies for the Thyroid-Associated Ophthalmopathy: Current and Future Perspectives
  103. Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor
  104. Hepatitis B and C
  105. High sensitivity C-reactive protein level in cerebrovascular accident
  106. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)
  107. Comparative analysis of Hemagglutinin of 2013 H3N2 Influenza A virus Indicates its Evolution from 1968 H3N2 Pandemic Influenza A virus
  108. Use of Mobile Phone Apps for Contact Tracing to Control the COVID-19 Pandemic: A Literature Review
  109. Next-Generation Rapid Advanced Molecular Diagnostics of COVID-19 by CRISPR-Cas
  110. A demographic prevalence of β Thalassemia carrier and other hemoglobinopathies in adolescent of Tharu population
  111. Animal Flaviviruses
  112. COVID-19: An Ophthalmological Update
  113. Classical Coronaviruses
  114. Clinical Characteristics and Differential Clinical Diagnosis of Novel Coronavirus Disease 2019 (COVID-19)
  115. Contemporary vaccine approaches and role of next-generation vaccine adjuvants in managing viral diseases
  116. Coping with Mental Health Challenges During COVID-19
  117. Coronavirus Disease 2019 (COVID-19)
  118. Coronavirus Infection Among Children and Adolescents
  119. Correction to: Transmission Cycle of SARS-CoV and SARS-CoV-2
  120. Current Advances in Nanotechnology and Medicine
  121. Current Insight into the Novel Coronavirus Disease 2019 (COVID-19)
  122. Diagnostic Strategies for COVID-19 and other Coronaviruses
  123. Emergence and Reemergence of Severe Acute Respiratory Syndrome (SARS) Coronaviruses
  124. Futuristic Technologies for Advanced Detection, Prevention, and Control of COVID-19
  125. Global Trends in Epidemiology of Coronavirus Disease 2019 (COVID-19)
  126. Host Immune Response and Immunobiology of Human SARS-CoV-2 Infection
  127. Laboratory Diagnosis of Novel Coronavirus Disease 2019 (COVID-19) Infection
  128. Modern Approaches in Nanomedicine for NeuroAIDS and CNS Drug Delivery
  129. Morphology, Genome Organization, Replication, and Pathogenesis of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
  130. NanoBioMedicine
  131. Nanotoxicology in Medicine
  132. Negative COVID-19 Test: What Next?
  133. Nipah Virus
  134. Opportunities in Clinical Translation and Commercialization of Nanomedicine
  135. Pandemic Influenza A Virus (pH1N1)
  136. Preparing Children for Pandemics
  137. Preparing for the Perpetual Challenges of Pandemics of Coronavirus Infections with Special Focus on SARS-CoV-2
  138. Prevention and Control Strategies for SARS-CoV-2 Infection
  139. Radiological Perspective of the Novel Coronavirus Disease 2019 (COVID-19)
  140. Therapeutic Development and Drugs for the Treatment of COVID-19
  141. Transmission Cycle of SARS-CoV and SARS-CoV-2
  142. Water-Associated Infectious Diseases
  143. Malaria
  144. Current Topics in Neglected Tropical Diseases
  145. The Global Distribution and Burden of Dengue and Japanese Encephalitis Co-Infection in Acute Encephalitis Syndrome
  146. Complementary and Alternative Medicine Treatments of Water-Associated Infectious Diseases in Alliance with Conventional Medicine Treatments
  147. Conventional Treatments of Water-Associated Infectious Diseases
  148. Emerging and Re-emerging Water-Associated Infectious Diseases
  149. Epidemiology of Water-Associated Infectious Diseases
  150. Etiological Agents of Water-Associated Infectious Diseases
  151. Evolution and Interplay of Water-Associated Human Pathogens
  152. Global Strategies and Schemes for Preventing Water-Associated Infectious Diseases
  153. Hazards Associated with Contaminated Water
  154. Impact of Climate Change on Water-Associated Infectious Diseases
  155. Introduction to Water-Associated Infectious Diseases
  156. Novel Approaches for Detecting Water-Associated Pathogens
  157. Treatment of Water to Prevent Water-Associated Infectious Diseases
  158. Correlation of Cytogenetic, Molecular and Clinical Findings in Thalassemia Patients at a Tertiary Care Hospital
  159. Hydroxyapatite–collagen augments osteogenic differentiation of dental pulp stem cells
  160. Cytogenetic Analysis of Down Syndrome Patients in Eastern Uttar Pradesh.
  161. Current Perspectives in Human Papillomavirus
  162. Recent Advances in Human Papillomavirus Infection and Management
  163. Pathogen-associated acute encephalitis syndrome: therapeutics and management
  164. Zika virus disease in India - Update October 2018
  165. Introductory Chapter: Human Influenza A Virus Infection - Global Prevalence, Prevention, Therapeutics, and Challenges
  166. Influenza - Therapeutics and Challenges
  167. Global Perspective of Novel Therapeutic Strategies for the Management of NeuroAIDS
  168. Introductory Chapter: Neglected Tropical Waterborne Infectious Diseases - Strategies for Mitigation
  169. Nanocarriers for brain specific delivery of anti-retro viral drugs: challenges and achievements
  170. Complementary and alternative medicine in alliance with conventional medicine for dengue therapeutics and prevention
  171. Reducing the Global Burden of Dengue: Steps toward Preventive Methods
  172. Mesenchymal stem cells in regenerative medicine: a new paradigm for degenerative bone diseases
  173. Current Advances in Zika Virus Transmission: Urgency for Effective Therapeutics and Prevention
  174. Complementary and alternative medicine in alliance with conventional medicine for influenza therapeutics and prevention
  175. Proof and Concepts in Rapid Diagnostic Tests and Technologies
  176. Introductory Chapter: Serum Components as Rapid Diagnostic Biomakers During Flavivirus Infection
  177. Emerging Zika virus disease: a public health emergency of global concern
  178. Advances in Molecular Retrovirology
  179. Molecular Biology and Pathogenesis of Retroviruses
  180. Zika virus outbreak: an overview of the experimental therapeutics and treatment
  181. Investigation of Neuropathogenesis in HIV-1 Clade B and C Infection Associated with IL-33 and ST2 Regulation
  182. Interactive effects of cocaine on HIV infection: implication in HIV-associated neurocognitive disorder and neuroAIDS
  183. Japanese encephalitis: a major public-health debacle
  184. Japanese Encephalitis: A Neglected Viral Disease and Its Impact on Global Health
  185. Trends in Infectious Diseases
  186. CURRENT SCENARIO OF THERAPEUTICS FOR EBOLA VIRUS DISEASE
  187. An insight into flaviviral budding: a need to know more
  188. Towards nanomedicines for neuroAIDS
  189. Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder
  190. Current Scenario of Antiviral Drugs for Japanese Encephalitis
  191. Cocaine Enhances HIV-1 Infectivity in Monocyte Derived Dendritic Cells by Suppressing microRNA-155
  192. Latency, persistence and reactivation of Japanese encephalitis virus
  193. Targeted Brain Derived Neurotropic Factors (BDNF) Delivery across the Blood-Brain Barrier for Neuro-Protection Using Magnetic Nano Carriers: An In-Vitro Study
  194. Current Perspectives in HIV Infection
  195. NeuroAIDS: Mechanisms, Causes, Prevalence, Diagnostics and Social Issues
  196. Latest trends in drugs of abuse – HIV infection and neuroAIDS
  197. Japanese Encephalitis Virus: The Complex Biology of an Emerging Pathogen
  198. Influenza A(H1N1)pdm09 virus: therapeutics and challenges
  199. A Global Perspective on HIV/AIDS
  200. Nanotherapeutics: emerging competent technology in neuroAIDS and CNS drug delivery
  201. Modulation of HIV pathogenesis and T-cell signaling by HIV-1 Nef
  202. Targeting Strategies for Human Immunodeficiency Virus: A Combinatorial Approach
  203. HIV-1 Nef: hacker of the host cell
  204. Rendezvous with Tat: Transactivator of Transcription during Human Immunodeficiency Virus Pathogenesis
  205. Japanese Encephalitis: A Persistent Threat
  206. The Intolerable Burden of Chikungunya: What’s New, What’s Needed?
  207. Interactive Effects of Morphine on HIV Infection: Role in HIV-Associated Neurocognitive Disorder
  208. JAPANESE ENCEPHALITIS VIRUS: AN EMERGING PATHOGEN
  209. Japanese Encephalitis: An Emerging and Spreading Arbovirosis
  210. HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: Implication for HIV-associated neurocognitive disorder (HAND)
  211. Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: Implications for neuroAIDS
  212. Interactive role of human immunodeficiency virus type 1 (HIV-1) clade-specific Tat protein and cocaine in blood-brain barrier dysfunction: Implications for HIV-1–associated neurocognitive disorder
  213. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors
  214. Escalation of Japanese encephalitis in India: Evidence from 2005 viral encephalitis outbreak and appraisal of niceties
  215. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors
  216. Structural and antigenic variance between novel influenza A/H1N1/2009 and influenza A/H1N1/2008 viruses
  217. Swine flu: Influenza A/H1N1 2009: the unseen and unsaid
  218. Trend of Japanese encephalitis in North India: evidence from thirty-eight acute encephalitis cases and appraisal of niceties
  219. Advances in antiviral drug discovery and development: Part II: Advancements in antiviral drug development
  220. Controversial role of smallpox on historical positive selection at the CCR5 chemokine gene (CCR5-Δ32)
  221. Paromomycin: Uptake and resistance in Leishmania donovani
  222. Advances in antiviral drug discovery and development: Part I: Advancements in antiviral drug discovery
  223. The Latitude Wise Prevalence of the CCR5-Δ32-HIV Resistance Allele in India
  224. Japanese encephalitis: perspectives and new developments
  225. Enzymatic and Structural Characterisation of Amphinase, a Novel Cytotoxic Ribonuclease from Rana pipiens Oocytes
  226. Re-emergence of the knotty chikungunya virus: facts, fear or fiction
  227. Differential HIV-1 replication in neonatal and adult blood mononuclear cells is influenced at the level of HIV-1 gene expression
  228. Co-administration of IL-12 DNA with rORFF antigen confers long-term protective immunity against experimental visceral leishmaniaisis
  229. Reply to 'Encephalitis outbreak finds Indian officials unprepared'
  230. A Heterologous Prime‐Boost Vaccination Regimen Using ORFF DNA and Recombinant ORFF Protein Confers Protective Immunity against Experimental Visceral Leishmaniasis
  231. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen
  232. ONCONASE ® and Its Therapeutic Potential
  233. Inhibition of Japanese Encephalitis Virus Infection by Diethyldithiocarbamate is Independent of its Antioxidant Potential
  234. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani
  235. Alteration in plasma glucose levels in Japanese encephalitis patients
  236. Entry into Cells and Selective Degradation of tRNAs by a Cytotoxic Member of the RNase A Family
  237. Induction of Nitric Oxide Synthase during Japanese Encephalitis Virus Infection: Evidence of Protective Role
  238. Antiviral effect of nitric oxide during Japanese encephalitis virus infection
  239. Regulation of intestinal regeneration: New insights
  240. Interferon Enhances the Activity of the Anticancer Ribonuclease, Onconase
  241. Engineering receptor-mediated cytotoxicity into human ribonucleases by steric blockade of inhibitor interaction
  242. Isolation of Desulfovibrio intestinalis sp. nov. from the hindgut of the lower termite Mastotermes darwiniensis
  243. Degradation of Japanese encephalitis virus by neutrophils
  244. Role of Organized Intestinal Lymphoid Aggregates in Intestinal Regeneration
  245. Inhibition of HIV-1 Production and Selective Degradation of Viral RNA by an Amphibian Ribonuclease
  246. Role of the N Terminus in RNase A Homologues: Differences in Catalytic Activity, Ribonuclease Inhibitor Interaction and Cytotoxicity
  247. A Study of the Intracellular Routing of Cytotoxic Ribonucleases
  248. Epithelial cell proliferation and biodistribution of radiolabeled urogastrone in the gastrointestinal mucosa of young and old mice
  249. Lignocellulose degradation by microorganisms from termite hills and termite guts: A survey on the present state of art
  250. Effect of systematic interleukin-3 administration on epithelial cell proliferation in mouse intestine
  251. Extent and Role of Urogastrone in the Adaptive Response of Rat Intestine to Patching of a Surgical Defect in the Ileum
  252. Ultrastructural studies of the termite (Odontotermes obesus) gut microflora and its cellulolytic properties
  253. Association of radiolabeled urogastrone binding with regenerating intestinal mucosa and epidermal growth factor/ urogastrone producing organs in rat
  254. Effect of cobalt and nickel on growth and carboxymethyl cellulase activity ofCellulomonas spp
  255. Production and localisation of carboxymethylcellulase, xylanase and ?-glucosidase fromCellulomonas andMicrococcus spp.
  256. The Effect of Intestinal Resection and Urogastrone on Intestinal Regeneration
  257. Ethanol Has Direct Inhibitory Effects on Steroidogenesis in Human Granulosa Cells: Specific Inhibition of LH Action
  258. Effect of age on intestinal regeneration in the rabbit
  259. Effect of Eflorithine on Intestinal Regeneration